about
Molecular signaling involving intrinsically disordered proteins in prostate cancerWhat we know and do not know about the cannabinoid receptor 2 (CB2)Oxylipins from Dracontium loretense.Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cellsp53 regulates the mevalonate pathway in human glioblastoma multiforme.From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.Characterization of linear mimetic peptides of Interleukin-22 from dissection of protein interfaces.Cannabinoids in the management of spasticity associated with multiple sclerosis.Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug.Potential therapeutic role of statins in neurological disorders.Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.Cannabinoid receptor CB1 antagonists state of the art and challenges.Statins in neurological disorders: an overview and update.Interactions of cisplatin analogues with lysozyme: a comparative analysis.Immuno-Modulatory and Anti-Inflammatory Effects of Dihydrogracilin A, a Terpene Derived from the Marine Sponge Dendrilla membranosaImmunomodulatory properties of 1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxamide derivative VL15.Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response.New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.Endocannabinoid System in Neurological Disorders.Cannabidiol: State of the art and new challenges for therapeutic applications.Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth.Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells.Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells.Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis.The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.Anandamide inhibits adhesion and migration of breast cancer cells.Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis.Comment on "the negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.".Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.Nucleophosmin-1 regions associated with acute myeloid leukemia interact differently with lipid membranes.N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.
P50
Q26747089-E0C97027-3956-43BE-95F8-E5A22FA48E2EQ27686851-7C94D90A-5A4A-492C-AAAE-D5BB44C7C640Q34606159-DD7AC2DA-B186-43C3-B15F-F7C3BA75B5FBQ34712554-63E74F7C-774F-492E-8E96-C41CE418598CQ36021048-EAD0ED41-AEF2-4F0D-ADAD-74CE1B55DD75Q36246455-271D0AF4-6B6F-4000-91AD-E729953E702FQ36352206-7B3AE80A-55A4-495C-92A9-047F189EB192Q36365118-531A3808-F5CF-4E28-B36C-57BA264C0021Q37062594-CF54003E-8B0C-48C7-AA7A-AA22B98634CFQ37089883-47320DFA-93B0-43E1-88C2-A88E2962FA4DQ37154822-B685B1BC-E04C-41A3-A792-0B1D9D5A8BD8Q37414563-CA2A1F15-1F0F-4CE3-A669-60053147CB76Q37568626-40151813-C7EA-439C-8EBF-F80A47F8DB22Q38222375-727093A5-B3EF-44B6-9C00-D284356E6F20Q38624654-FEE297B3-E201-4090-9393-5D2BBD4076C6Q38695506-4A3C5C7A-D734-43AA-8165-17C5A30AB58BQ38715594-3B65FC3A-35CC-4A26-8551-40BAE555117DQ38835655-9219B687-9827-45B1-88C4-6DEAAD5F0066Q38849542-58FE027C-3D88-4731-A3B4-5DDB58A659C3Q38873824-6D7EC73C-B7BA-4706-B01C-1A49E62589C9Q38879833-45361454-7AF9-4C6B-AEC8-4AA19AE0791DQ38882455-EA5454A4-8FEC-4A11-AB85-89F5F309F26BQ39148525-F812E674-6C61-42FB-AAD0-58F672770DC0Q39368198-696442A8-EFC6-4438-A121-62FCF4406049Q39436245-1541B2E7-4327-4836-AE77-F4A1AF8A3363Q39574967-6ACFF8BF-9AE8-4CCD-A920-0A845B767E72Q39673619-79BC7B98-773C-47E5-B6DD-DC08E69F9D54Q39725206-D4530B80-4093-47E9-99F1-174010235084Q39767814-2D611DEF-0799-4DDB-9A97-0E767FFC9BE2Q39836397-4243F4D3-76C3-41D4-BEAF-2095B969B804Q40258566-8E2C85BE-AF73-448F-8FD4-D1DEF70B786AQ40341063-D1FA2F4C-0DEF-4910-BC83-F27D066249CEQ40359790-5A63C6CA-5768-4309-A8D9-C53469E9CA92Q43175222-5B0D8CC4-5846-4515-A6D8-FF788BE82559Q45990811-FFE0016F-1333-4499-8E8F-DCB7E4770420Q46639864-A13BF960-01A4-4574-A73C-D4FAC5C0CC3AQ48965109-85F3E94C-7C5E-4A3B-A998-C3838CA2B271Q50060183-AB0C401D-59FA-4E61-997B-831D6B4F7D97Q51778118-C667437B-3674-4020-9DC0-07314FCD416EQ54394949-252D73DD-F05A-4FC3-919E-401DEAC27703
P50
description
researcher ORCID ID = 0000-0002-6193-2835
@en
wetenschapper
@nl
name
Anna Maria Malfitano
@ast
Anna Maria Malfitano
@en
Anna Maria Malfitano
@es
Anna Maria Malfitano
@nl
type
label
Anna Maria Malfitano
@ast
Anna Maria Malfitano
@en
Anna Maria Malfitano
@es
Anna Maria Malfitano
@nl
prefLabel
Anna Maria Malfitano
@ast
Anna Maria Malfitano
@en
Anna Maria Malfitano
@es
Anna Maria Malfitano
@nl
P106
P21
P31
P496
0000-0002-6193-2835